This guideline was developed by a multidisciplinary task force and uses the GRADE framework to provide evidence-based recommendations regarding cardiovascular risk assessment, benefits and harms of newer medications, and treatment goals with a focus on patient-important outcomes.

This updated guideline provides recommendations for the care and management of people with or at risk for diabetes mellitus at every stage, including prevention, diagnosis, and treatment.

This guideline provides evidence-based recommendations regarding the diagnosis and management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) to endocrinologists, primary care clinicians, health care professionals, and other stakeholders.

Advanced diabetes technology can potentially assist persons with diabetes to achieve glycemic targets, improve quality of life, reduce burden of care, offer a personalized approach to self-management, and improve the efficiency of clinical decision-making, among other benefits. This guideline provides recommendations on the efficacy and safety of advanced diabetes technology devices for management of persons with diabetes mellitus, metrics used to aide with the assessment of advanced diabetes technology, and standards for implementation of this technology.

This guideline provides recommendations to reduce a person's risk of osteoporosis-related fractures and to evaluate, diagnose, and treat osteoporosis in postmenopausal women, based on fracture presence, assessment of fracture risk/probability, measurement of bone mineral density or bone mass, and a patient’s history, among other factors. An update of this guideline is currently in development.

This guideline provides recommendations on identification, screening, assessment, diagnosis, and treatment of a range of individuals with various causes of adult growth-hormone deficiency (GHD) and patients with childhood-onset GHD transitioning to adult care. The guideline summarizes current knowledge about the accuracy of available GH–stimulation tests, safety of recombinant human GH (rhGH) replacement, unapproved uses of rhGH related to sports and aging, and new developments such as long-acting GH preparations that use a variety of technologies to prolong GH action.

This guideline identifies patient candidates for bariatric procedures, discusses which types of bariatric procedures should be offered, outlines management of patients before procedures, and recommends how to optimize patient care during and after procedures.

This 2017 guideline‒led by the Endocrine Society and co-sponsored with AACE, American Society of Andrology, European Society for Pediatric Endocrinology, European Society of Endocrinology, Pediatric Endocrine Society, and World Professional Association for Transgender Health‒is an update of the 2009 Endocrine Society guideline on endocrine treatment of transsexual persons. An update of this guideline is in development.

The 2016 guideline and algorithm address key aspects of obesity care: screening, diagnosis, clinical evaluation, treatment options, therapy selection, and treatment goals.

This clinical practice guideline covers diagnostic and therapeutic aspects of thyroid nodular disease but not thyroid cancer management.

This guideline provides recommendations for diagnosis and clinical management of patients with hypothyroidism in the ambulatory care setting.

This guideline provides evidence-based recommendations for the management of patients with thyrotoxicosis.